Roma Kaul, PhD
About Roma Kaul, PhD
Roma Kaul, PhD, is a Senior Scientist at Leap Therapeutics, specializing in cancer biology, immunology, pharmacology, and biochemistry. Her research includes the anti-mitotic effects of microtubule targeting agents in breast cancer and the role of the NRF2 antioxidant in lung cancer.
Work at Leap Therapeutics
Roma Kaul serves as a Senior Scientist at Leap Therapeutics, a position she has held since 2024. In this role, she contributes to the company's research initiatives in cancer treatment, leveraging her extensive background in cancer biology and pharmacology. Her work focuses on developing innovative therapeutic strategies aimed at improving patient outcomes in oncology.
Education and Expertise
Roma Kaul holds a Bachelor of Engineering in Biotechnology from PES University, completed in 2013. She pursued her Doctor of Philosophy in Integrated Biomedical Sciences at UT Health San Antonio, graduating in 2019. Additionally, she completed a Postdoctoral Fellowship in Oncology and Cancer Biology at Harvard Medical School from 2019 to 2022, where she conducted significant research on the role of NRF2 in lung cancer.
Background
Roma Kaul's research background encompasses multiple disciplines, including cancer biology, immunology, pharmacology, and biochemistry. She began her research career as a Summer Research Intern at HealthCare Global in 2010, focusing on cancer research and treatment. Over the years, she has held various research positions, including a Research Fellow at St Johns Research Institute and a Scientist at Ribon Therapeutics.
Achievements
During her tenure at Ribon Therapeutics, Roma Kaul contributed to advancing clinical programs by conducting pre-clinical studies. Her graduate research focused on the anti-mitotic effects of microtubule targeting agents in breast cancer, which has implications for therapeutic development in oncology. Her work continues to influence cancer research and treatment strategies.